Department of Neurology and Mayo Clinic Alzheimer Research Center, Mayo Clinic, Rochester, MN 55905, USA.
Cell Rep Med. 2023 Mar 21;4(3):100982. doi: 10.1016/j.xcrm.2023.100982.
Lecanemab cleared amyloid-β in two-thirds and reduced the rate of cognitive and functional worsening in people with mild cognitive impairment and mild dementia due to Alzheimer disease in an 18-month double-blinded randomized placebo-controlled trial reported by van Dyck et al.
van Dyck 等人报告的一项为期 18 个月的双盲随机安慰剂对照试验显示，仑卡奈单抗清除了三分之二的淀粉样蛋白-β，降低了轻度认知障碍和轻度阿尔茨海默病性痴呆患者认知和功能恶化的速度。
